Phisitkul Sorot
Texas Tech University Health Sciences Center, Nephrology Division, 5103 Amherst, Lubbock, TX 79416, USA.
Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
CYT-006-AngQb, under development by Cytos Biotechnology AG, is a vaccine in which a peptide derived from the angiotensin II molecule is conjugated to the surface of the highly repetitive structure of virus-like particles. CYT-006-AngQb was designed to treat hypertension with the benefit of relatively long-lasting effects that do not require daily dosing. In spontaneously hypertensive rat models, CYT-006-AngQb induced strong angiotensin-II-specific antibodies and reduced systolic blood pressure. In a phase I clinical trial, single doses of CYT-006-AngQb were well tolerated in healthy males. In a phase II trial, multiple doses of CYT-006-AngQb administered to patients with mild-to-moderate hypertension reduced blood pressure; the average half-life was longer than all currently available oral hypertension medications. There were no significant side effects except for local skin reactions at the injection site. Given the novel mechanism of CYT-006-AngQb, and the potential to complement other hypertension treatments, success in ongoing phase II trials in patients with hypertension would potentially make this therapy a valuable addition to the therapeutic armamentarium for hypertension.
CYT-006-AngQb由Cytos Biotechnology AG公司研发，是一种疫苗，其中源自血管紧张素II分子的一种肽与病毒样颗粒的高度重复结构表面结合。CYT-006-AngQb旨在治疗高血压，具有相对持久的效果，无需每日给药。在自发性高血压大鼠模型中，CYT-006-AngQb诱导产生强烈的血管紧张素II特异性抗体并降低收缩压。在一项I期临床试验中，健康男性对单剂量的CYT-006-AngQb耐受性良好。在一项II期试验中，给予轻至中度高血压患者多剂量的CYT-006-AngQb可降低血压；其平均半衰期比所有目前可用的口服抗高血压药物都长。除注射部位出现局部皮肤反应外，无明显副作用。鉴于CYT-006-AngQb的新机制以及补充其他高血压治疗方法的潜力，正在进行的高血压患者II期试验若取得成功，可能会使这种疗法成为高血压治疗手段中有价值的补充。
